Zhishan Weixin Snares ￥100M in Series A Funding Round

(VCBeat) Feb. 9, 2021 -- Recently, Sichuan Zhishan Weixin Biological Technology Co., Ltd. ("Zhishan Weixin"), a gene therapy company, announced it has raised hundreds of millions in Series A funding round, led by Loyal Valley Capital, with participation from Morningside Group, Delian Capital, Junshi Biosciences, Leimerious and the existing investor Sichuan Talent Fund. Haoyue Capital acted as the financial advisor.

Established in 2018, Zhishan Weixin is a leading gene therapy company focusing on the R&D of recombinant adeno-associated virus (rAAV) drugs. The company has a professional team in the field of gene therapy. The founder Dong Biao has been engaged in the research of rAAV vectors for more than ten years and has made breakthroughs in the design and large-scale production of gene therapy drugs.

Zhishan Weixin's pipeline covers the treatments of blood diseases, rare diseases and others. The company has highly active gene sequences related to a number of diseases and are expected to been developed into best-in-class drugs. The company has the world's leading production system for rAAV, which overcomes the bottleneck of large-scale production of rAAV at a very low cost. This revolutionary production system is expected to significantly reduce the cost of gene therapy treatment and greatly improve the accessibility of gene therapies.

LVC is a thematic, research-driven private equity firm that invests in middle-market companies positioned to benefit from the secular industry transformation in China. With over US$2 billion of AUM, LVC focuses on four segments: New Consumer, Healthcare, Specialty Industrials, and Financial Services.

Morningside Group is a private investment group founded in 1986 by the Chan family of Hong Kong. Morningside Group invests in private equity and venture capital opportunities in North America, Europe and Asia Pacific. Morningside Group has investments in the following sectors -- machinery manufacturing, high-tech, media, telecommunication, life science, education and cleantech.